Publications by authors named "W Boreland"
In patients diagnosed with B-acute lymphoblastic leukemia (B-ALL) or B-non-Hodgkin's lymphoma (B-NHL) relapsing after allogeneic stem cell transplantation (allo-HCT), it is a standard practice to perform anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. When collected from the patient after allo-HCT, the produced CAR-T cells are likely to be donor T-cell-derived, creating unknown safety risks due to their potential allo-reactivity. We therefore performed an EBMT registry-based study on the incidence of graft-versus-host disease (GvHD) in this setting.
View Article and Find Full Text PDFArticle Synopsis
- Scientists are unsure when to do a second stem cell transplant for patients with blood cancer who relapse after the first one.
- A study looked at 3,356 patients who had a second transplant from 2011 to 2021 and found that 22% did not survive due to reasons other than their illness.
- The research suggests it's safe to consider more second transplants and points out important risks to keep in mind, like age and how quickly the cancer returned.
The EBMT (European Blood and Marrow Transplantation Society) aims to connect patients, the scientific community, and other stakeholders to improve hematopoietic stem cell transplantation and cellular therapy outcomes. We performed a cross-sectional online survey to understand the perceptions regarding Patient Reported Outcomes (PROs) and Patient Active Involvement in Research (PAIR) in over 800 stakeholders (n = 813). Patients (n = 278) and health care professionals (HCPs) (n = 351) were compared.
View Article and Find Full Text PDF